8-K current report · filed Oct 14, 2026

Enliven Therapeutics, Inc. (ELVN) 8-K Current Report: October 14, 2026

Item EX-99.1Item 5.02Item 7.01ELVN overview

Short answer

Enliven Therapeutics, Inc. (ELVN) filed an 8-K current report with the SEC on October 14, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Board expanded from seven to eight directors, adding Kristine Ball as a Class II director through the 2028 annual meeting.

Enliven Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Board expanded from seven to eight directors, adding Kristine Ball as a Class II director through the 2028 annual meeting
  • Ball joins the Audit Committee, strengthening board-level financial oversight
  • Annual compensation totals $55,000, including $45,000 as director and $10,000 for Audit Committee service
  • Stock options granted with approximately $650,000 fair value, vesting monthly over 36 months
  • Full option acceleration upon a change in control, increasing potential transaction-related dilution for shareholders

Item 7.01 · Regulation FD Disclosure

  • Board appointment of Ms. Ball announced October 14, 2026
  • Leadership addition may influence governance and strategic oversight
  • Exhibit 99.1 contains the appointment press release

Item EX-99.1 · Exhibit EX-99.1

  • Kristine Ball appointed to Enliven’s board, adding biotechnology expertise in finance, strategy, governance and commercial readiness
  • Appointment supports planned transition from clinical development toward commercialization
  • Pivotal ENABLE-2 Phase 3 trial of relcobatinib planned before year-end 2026
  • FDA alignment on ENABLE-2’s final design reduces a key trial-planning uncertainty
  • Key risks remain trial delays, inadequate efficacy or safety, regulatory setbacks and additional capital requirements

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Enliven Therapeutics, Inc. 8-K filings

Get the next ELVN 8-K as it lands

Follow ELVN for push alerts, or ask the research agent what this filing means.